Abstract: Ureteral stents are commonly used in urology but are frequently associated with patient discomfort, stent encrustation and stent-related infection. New biomaterials, coatings and designs have been designed to attempt to reduce these problems. This article reviews coatings to reduce bacterial adhesion and encrustation. In addition, metal ureteral stents, the triclosan and ketorolac drug eluting ureteral stents, and biodegradable ureteral stents are discussed. In summary there is no perfect ureteral stent that avoids all morbidity but there have been significant advances in the last few years in stent technology.
Introduction
The most common problems associated with indwelling ureteral devices are encrustation, bacterial adhesion and biofilm formation on the device surface. Even in patients in whom infection does not develop, bacteria are often isolated from the stent surface despite the collection of sterile urine [Akay et al. 2007; Paz et al. 2005] . Encrustation is often associated with an increase in urinary pH as a result of infection by urease-producing bacteria, which break down urea to ammonium making the urine more alkaline, an environment that favors bacterial growth and precipitation of struvite [Jones et al. 2006; Watterson et al. 2003 ]. Various other technologies have been implemented to improve the problems associated with ureteral stents. Most notably, new biomaterials that are either softer or firmer, or even have drugs loaded into the bulk material that elute over time to combat problems such as pain and infection have been used.
Stent coatings to reduce bacterial adhesion
The design of new stent biomaterials has focused on the inhibition of device encrustation and bacterial adhesion and has taken many approaches including inhibitory coatings and materials. Glycosaminoglycans are a normal constituent of urine and have been shown to be natural inhibitors of crystal formation by binding to urinary components and blocking sites that are involved in crystal growth [Yoshimura et al. 1997; Angell and Resnick, 1989] . Heparin has previously been found to have the strongest inhibitory effect of all glycosaminoglycans and has recently been placed on the surface of stents in an attempt to inhibit encrustation [Cauda et al. 2008] . Using an in vitro model, Hildebrandt et al. recently showed that heparin-coated stents showed no encrustation following 7 days of continuous exposure to artificial urine compared with uncoated controls which showed significant amounts of encrustation [Hildebrandt et al. 2001] . In a subsequent in vivo experiment, the uncoated control-stents showed significant encrustation after 120 days indwelling with two of the 20 stents being completely obstructed. In comparison the heparincoated stents contained only small amounts of deposits on their surface and did not show any signs of obstruction [Hildebrandt et al. 2001 ].
Riedl et al. performed a prospective, randomized study in which 20 heparin-coated and 20 uncoated polyurethane-stents were inserted into obstructed ureters and left indwelling for 26 weeks [Riedl et al. 2002] . In addition to this, two patients received two nephrostomy tubes each, one heparin-coated and one uncoated to allow for direct comparison. Two weeks postinsertion, the control stents were found to contain mineralized crystals as well as biofilm, while mild encrustation was found on heparin-coated stents after 6 weeks of indwelling time. Despite the fact that the microscopy suggested the presence of bacterial biofilms on uncoated stents, no cultures were performed in this study to confirm this finding. Similarly, the heparin-coated nephrostomy tubes remained patent over the 68 week period, while the uncoated tubes became completely obstructed within 23 weeks. This pilot study further confirmed in an in vivo setting that heparin coating significantly decreases stent encrustation. A more recent in vivo case-study tested the ability of heparin-coated stents to inhibit encrustation in five patients with bilateral obstruction [Cauda et al. 2008] . Every patient received a heparin-coated stent and a conventional polyurethane-stent for comparison, and the devices were left indwelling for 1 month. Two patients had the stents in place for 10 and 12 months respectively. Upon removal after 1 month, the control stents contained crystalline deposits as well as biofilm, although this was again not confirmed by culture results. Overall, the heparincoated stents had less encrustation with some having a layer of encrustation present on the surface, which was thinner than those on the control stents. Interestingly the stents that were removed after 10 and 12 months did not show any signs of encrustation, although the 12-month stent did appear to have bacterial biofilm on its outer surface. The fact that different results were obtained between patients seems to suggest that patient factors play a role in the effectiveness of the coating at inhibiting encrustation. It is important to note that indwelling time did not have an effect on the thickness of the heparin coating, indicating that covalently bonding the material to the polyurethane stent is very stable. Based on the most recent literature available on inhibitory stent coatings, the consensus is that heparin effectively prevents device encrustation.
Despite the fact that all of the aforementioned studies address encrustation as a result of stent indwelling, none address how the stent behaves in the setting of a bacterial infection and subsequent encrustation. Tenke et al. reported on ten patients with permanent ureteral-stent drainage in which heparin-coated stents were left indwelling for 68 months [Tenke et al. 2004] . In all patients, bacteriuria was present at the time of stent insertion, likely as a result of the previous indwelling stent. No obstruction or blockage of the stents was observed, and the level of encrustation was found to be minimal. In three patients with uretero-enteral anastomotic strictures in an ileal conduit, heparin stents were left indwelling for 12 months, and none of the heparin-coated stents were encrusted or showed biofilm formation in this bacteria exposed environment. Despite the fact that bacteria were present in this study, it cannot be concluded that heparin inhibits infection-related encrustation as it depends on whether the infecting bacterial species were urease positive or negative. It is therefore still uncertain how effective the heparin stent is in an environment in which urease positive bacteria are present.
More recently, our group tested the ability of common pathogens to adhere to, and form, biofilms directly on commercially available stents. For this, heparin-coated ureteral stents [Radiance Õ , Cook Medical (not available in the United States)] and non-coated controls (EndoSof Õ , Cook Medical) were tested against Triclosan eluting stents [Triumph Õ , Boston Scientific (not available in the United States)] and non-eluting controls (Polaris Õ , Boston Scientific) for adherence of E. coli, K. pneumoniae, E. faecalis, S. aureus, and P. aeruginosa for 7 days ]. Overall, no significant differences were observed in the number of bacteria adhered to the Resonance and Endo-Sof control stents indicating that heparin is not inhibitory to direct bacterial adhesion to its surface. Making a stent coating that prevents bacterial adhesion is complicated by the highly-variable mechanisms utilized by bacteria for attaching to surfaces including specific receptors, proteins, overall surface charge and surface carbohydrates. Studies looking at the ability of E. coli to adhere to surface modified silicone have shown that heparin-coated silicone attracted more bacteria than other surfaces [Cao et al. 2006] . It has previously been shown that charged groups found in the O-antigen of lipopolysaccharide (LPS) facilitate adhesion of E. coli to negatively-charged surfaces [Abu-Lail and Camesano, 2003 ], which explains a high attraction of Gram-negative bacteria such as E. coli, P. aeruginosa, and K. pneumoniae towards the strongly negatively-charged heparin and hydrophilic polymer surfaces. Similarly, heparin has also been shown to stimulate the formation of S. aureus (Gram-positive) biofilms on various surfaces and even had the ability to trigger biofilm formation in a known biofilm-mutant [Shanks et al. 2005] , by increasing cellcell interactions. Several studies also report a S. aureus heparinbinding protein, which would facilitate binding of the bacterium to heparin-coated stents [Fallgren et al. 2001; Liang et al. 1992] . As a result stent design will need to focus on addressing the inhibition of multiple factors, such as a biomaterial that may be inhibitory to one factor may promote the occurrence of another. Other glycosaminoglycans such as pentosanpolysulfate have shown promise in decreasing encrustation and the inflammatory response of surrounding ureteral tissue which may warrant further study [Zupkas et al. 2000] . The ability of ureteral stents coated with plasma deposited diamondlike amorphous carbon (DLC) to inhibit encrustation was tested in ten patients with different disease-patterns and different indications for stenting, who were determined to have had encrustation of conventional stents previously [Laube et al. 2007; . This study showed that DLC-coated stents had decreased friction, improved patient comfort and decreased encrustation. The authors indicate that DLC coatings on stents are inhibitory to bacterial adhesion and biofilm formation, however, there appears to be no direct evidence for this from either in vivo or in vitro experiments. Nonetheless, DLC-coated stents appear to provide relief for patients, however, the mechanisms for this still remain to be determined.
Drug-eluting ureteral stents
Drug eluting technology has made significant progress over the past five years and shows the most promise at addressing stent-related morbidity. Recently Chew et al. have tested a triclosaneluting stent which was shown to inhibit the growth of E. faecalis, S. aureus, P. mirabilis, and K. pneumoniae, and downregulated E. coli virulence factor promoters and decreased the survival of P. mirabilis and associated inflammation in an in vivo rabbit infection model . These results indicate that the triclosan-eluting stent addressed two of the most common complications of indwelling ureteral stents: infection and discomfort. This anti-inflammatory effect of triclosan was further shown in a novel in vitro model addressing ureteral stent-induced cell injury in which pro-inflammatory cytokine release by kidney and bladder cells upon mechanical injury was decreased when cell injury was induced by the triclosan-eluting stent or when triclosan was added to cells injured with a control stent . In fact Elwood et al. have shown that triclosan inhibited tumornecrosis-factor alpha production by bladder cells infected with uropathogenic E. coli (UPEC) [Elwood et al. 2007] . Despite the fact that there is no direct evidence for the development of triclosan-resistant bacteria, the triclosan-eluting stent is no longer commercially available due to concerns of resistance.
Drug-eluting technology has also recently been used in an attempt at preventing stent-associated pain symptoms. Liatsikos et al. tested a paclitaxel-eluting metal stent, normally used in cardiac conditions, and found it decreased the amount of inflammation and hyperplasia in a pig model compared with the non-eluting controls [Liatsikos et al. 2007] . This particular stent is still awaiting human clinical trials. Similarly, a ketorolac-eluting ureteral stent (Lexington TM stent, Boston Scientific) was designed in an attempt to decrease stent-associated pain. A pig model which was aimed at determining the safety and tissue levels of ketorolac showed that the plasma levels of ketorolac were approximately 11 times lower in the drugeluting stent (DES) compared with the control group which had ketorolac administered orally [Chew et al. 2009a] . For the animals treated with the DES, the ketorolac levels were found to be highest in the ureteral tissue, which is the intended target of the drug. This indicates that DESs are able to deliver high concentrations of the drug to the local area, keeping systemic levels and therefore serious side-effects at a minimum. In a subsequent clinical study, 276 patients were randomized to receive a ketorolac impregnated drug-eluting stent (13% drug by weight) or a control nondrug-eluting stent for up to 10 days. Despite the fact that this trial did not show improvement in stent symptoms by the DES, a trend toward less narcotic usage in younger males was observed [Lingeman et al. 2009 ].
Metal ureteral stents
Tight ureteral compression can occur from external compression such as from a large impinging tumor or adenopathy. Internally, ureteral strictures can be difficult to maintain luminal patency. In order to circumvent complications associated with these two problems, metal stents (MS) were developed. To date, several different types of MS exist including a self-expandable stent, balloon expandable, covered and thermoexpandable shape-memory MS (Memokath 051; Engineers and Doctors a/s, Hornbaek, Denmark). The overall consensus of studies aimed at testing different MS is that these devices are efficient at maintaining patency over prolonged periods of time in patients with ureteric compression due to varying malignancies. A recent prospective study performed by Liatsikos et al. found that the Resonance stent (Cook Medical, Bloomington, Indiana) maintained patency in 100% of patients with extrinsic ureteral-obstruction secondary to malignant ureteric-obstruction but only in 44% of patients with benign ureteralobstruction indicating that its use in the latter cases may not be a suitable option and requires further investigation [Liatsikos et al. 2009a] . Similar results were also found by Li et al. who found that the use of a metal stent is a safe and effective treatment for benign upper urinary tract occlusions in selected cases [Li et al. 2007] . In addition to this, Wah et al. found that in three of 15 patients treated for ureteric obstruction due to varying malignancies, the Resonance stent failed due to bulky pelvic malignancy putting high external pressure on the ureteral wall and device [Wah et al. 2007 ]. This indicates that under certain conditions, the use of a metal stent may need to be re-evaluated, especially since it provides less overall urine flow compared to a standard stent [Blaschko et al. 2007] . In contrast to their non-metallic counterparts, there have been no reports of urinary tract infections associated with MS. In contrast to infections, stent encrustation remains a problem with the MS with several studies reporting light to serious encrustation of indwelling devices. Liatsikos et al. determined that 12 of 54 (22%) Resonance stents placed in 50 patients with extrinsic malignant obstruction were encrusted with a mean follow-up period of 8.5 months [Liatsikos et al. 2009] .
A metal coil reinforced stent with a polyurethane material is also available (Silhouette Stent, Applied Medical, Rancho Santa Margarita, CA) and has been shown to have greater resistance to external compression compared to regular plastic stents [Christman et al. 2009 ] and even the allmetal Resonance stent [Pedro et al. 2007] . Metal stents offer a distinct advantage over plastic polymer stents in the treatment of ureteral strictures or malignant ureteric obstruction. The cost of these stents is typically higher than regular stents, but may result in fewer stent changes and preclude a nephrostomy tube which would be a cost-saving measure. The other alternative is to place two double-J stents in the same ureter so that drainage may occur between the two stents [Hafron et al. 2006; Rotariu et al. 2001] . Metal-stent technology does offer significant compression resistance and whether they offer more resistance to encrustation and infection is still to be determined. Full-length metal stents have been tested to see if they interfere with shockwave lithotripsy or external beam radiotherapy and have been found to be unaffected and compatible with both procedures [Liatsikos et al. 2009b, c] . [Lingeman et al. 2003b ]. All stent material had passed out of the body within 4 weeks with only 1 stent prematurely migrating into the bladder at day 1. A phase II trial of the TUDS stent evaluated 88 patients following ureteroscopy and the stents were eliminated from the ureter at a median time of 8 days and eliminated completely from the body at a median of 15 days [Lingeman et al. 2003a] . By 30 days, 84% (74/88) of the stents had completely degraded. Unfortunately, in three patients, there were stent fragments that remained at 3 months and these patients required surgical intervention for removal. For the majority of patients (78.2%), the stent was effective at providing upper tract drainage for at least 48 hours post-operatively-the targeted time to define success. Due to the manufacturer's concerns about retained fragments, the TUDS stent is no longer available.
A more recent degradable stent composed of L-lactide, glycolide, and copolyester components similar to those found in absorbable sutures has been developed and tested in a porcine model (Uriprene TM , Poly-Med Inc, Grenville, SC) [Hadaschik et al. 2008] . The first-generation degraded in 710 weeks and while it provided excellent drainage with minimal hydronephrosis compared with control biostable stents, the axial rigidity was too soft resulting in difficulty advancing the stent directly over a guidewire. Insertion was required through a 10 Fr sheath over a hydrophilic wire. Furthermore, it was thought that 710 weeks was longer than stents are typically left indwelling following uncomplicated ureteroscopy. Although there was actually less bacterial adherence to the degradable stents, it was thought that this time frame was too long.
The next generation of degradable Uriprene stent was developed to degrade faster and was reinforced to provide better axial rigidity, thus making insertion over a regular polytetrafluoroethylene wire (without a 10 Fr sheath) possible [Chew et al. 2009b] . The degradation time also decreased so that 80% of the stents degraded over 23 weeks with 100% of stents being completely eliminated by week 4. The stent was very biocompatible on histology and did not result in any hydronephrosis in comparison to the control biostable stents. Drainage was also superior to control stents as seen by weekly intravenous pyelograms. This stent awaits clinical trials.
Conclusion
Ureteral stents continue to improve. The major advance we have seen in the last few years is that of full-length metal and metal-reinforced stents as well as drug eluting stents. Newer biomaterials and drugs will be used to combat the common problems of stent discomfort, encrustation and infection.
